title: Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110β.
abstract: Activation of the PI3K pathway occurs commonly in a wide variety of cancers. Experience with other successful targeted agents suggests that clinical resistance is likely to arise and may reduce the durability of clinical benefit. Here, we sought to understand mechanisms underlying resistance to PI3K inhibition in PTEN-deficient cancers. We generated cell lines resistant to the pan-PI3K inhibitor GDC-0941 from parental PTEN-null breast cancer cell lines and identified a novel PIK3CB D1067Y mutation in both cell lines that was recurrent in cancer patients. Stable expression of mutant PIK3CB variants conferred resistance to PI3K inhibition that could be overcome by downstream AKT or mTORC1/2 inhibitors. Furthermore, we show that the p110β D1067Y mutant was highly activated and induced PIP3 levels at the cell membrane, subsequently promoting the localization and activation of AKT and PDK1 at the membrane and driving PI3K signaling to a level that could withstand treatment with proximal inhibitors. Finally, we demonstrate that the PIK3CB D1067Y mutant behaved as an oncogene and transformed normal cells, an activity that was enhanced by PTEN depletion. Collectively, these novel preclinical and clinical findings implicate the acquisition of activating PIK3CB D1067 mutations as an important event underlying the resistance of cancer cells to selective PI3K inhibitors.
authors.affiliation: Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
authors.forename: Yoshito
authors.initials: Y
authors.lastname: Nakanishi
authors.affiliation: Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
authors.forename: Kimberly
authors.initials: K
authors.lastname: Walter
authors.affiliation: Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
authors.forename: Jill M
authors.initials: JM
authors.lastname: Spoerke
authors.affiliation: Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
authors.forename: Carol
authors.initials: C
authors.lastname: O'Brien
authors.affiliation: Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
authors.forename: Ling Y
authors.initials: LY
authors.lastname: Huw
authors.affiliation: Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.
authors.forename: Garret M
authors.initials: GM
authors.lastname: Hampton
authors.affiliation: Department of Oncology Biomarker Development, Genentech, Inc., South San Francisco, California. lackner.mark@gene.com.
authors.forename: Mark R
authors.initials: MR
authors.lastname: Lackner
mesh_terms: D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D045744:Cell Line, Tumor; D058534:Class I Phosphatidylinositol 3-Kinases; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D009154:Mutation; D051059:PTEN Phosphohydrolase / Q000172:deficiency; D019869:Phosphatidylinositol 3-Kinases / Q000235:genetics / Q000502:physiology; D000081082:Phosphoinositide-3 Kinase Inhibitors
chemical_list: D058534:Class I Phosphatidylinositol 3-Kinases; D051059:PTEN Phosphohydrolase; D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors; C497132:PIK3CB protein, human; C494929:PTEN protein, human